Pharmacist-Initiated Management of a Suspected Case of Risperidone-Induced Neuroleptic Malignant Syndrome in an Aged-Care Resident. The Role of Residential Medication Management Reviews in Medication Safety

Abstract

A 70-year-old female aged-care resident was referred by her general practitioner for a residential medication management review after nurses reported difficulties with swallowing, episodes of hyperthermia, elevated blood pressure, and tachycardia. These symptoms were accompanied by increasing confusion and drowsiness. Risperidone had recently been prescribed to treat behavioral and psychological symptoms of dementia. This case study describes the pharmacist-initiated management of the symptoms through a national medication review program. It demonstrates the valuable role collaborative medication reviews play in managing adverse drug reactions in aged-care.

Keywords

long-term care aged-care adverse drug reaction neuroleptic malignant syndrome or NMS and medication review

Get full access to this article

View all access options for this article.

References

Modi

Dharaiya

Schulz

Panayiotis

. Neuroleptic malignant syndrome: complications, outcomes and mortality. Neurocrit Care. 2016;24(1):97–103.

Pileggi

Cook

. Neuroleptic malignant syndrome: focus on treatment and rechallenge. Ann Pharmacother. 2016;50(11):973–981.

Tse

Barr

Scarapicchia

Vila-Rodriguez

. Neuroleptic malignant syndrome: a review from a clinically oriented perspective. Curr Neuropharmacol. 2015;13(3):395–406.

Reulbach

Dütsch

Biermann

, et al. Managing an effective treatment for neuroleptic malignant syndrome. Crit Care. 2007;11(1):R4.

Antai-Otong

. Pharmacological management of psychosis in Alzheimer’s disease: clinical challenges associated with second-generation antipsychotic medications. Perspect Psychiatr Care. 2008;44(2):120–123.

Westbury

Gee

Ling

Kitsos

Peterson

. More action needed: psychotropic prescribing in Australian residential aged care. Aust N Z J Psychiatry. 2019;53(2):136–147. doi:10.1177/0004867418758919.

Australian Government. Department of Health. The pharmaceutical benefits scheme; 2018. www.pbs.gov.au/medicine/item/3169T-8789N

Australian Institute of Health and Welfare. Dementia among Aged Care Residents: First Information from the Aged Care Funding Instrument. Aged care statistics series no. 32 Cat. no. AGE 63. Canberra, Australia: AIHW; 2011.

Australian Association of Consultant Pharmacy (AACP). Fact sheet No. 2. The facts on remuneration for medicines reviews. 2006. https://aacp.com.au/wp-content/uploads/2016/02/No-2-Remuneration-for-MMRs-July-2016.pdf.

10.

Australian Association of Consultant Pharmacy (AACP). [28/3/2018]. https://aacp.com.au.

11.

Australian Association of Consultant Pharmacy (AACP). [28/3/2018]. What are MMRs; 2017. https://aacp.com.au/what-are-mmrs/.

12.

Chen

. Pharmacist-led home medicines review and residential medication management review: the Australian model. Drugs Aging. 2016;33(3):199–204.

13.

Nishtala

Hilmer

McLachlan

Hannan

Chen

. Impact of residential medication management reviews on drug burden index in aged care homes. Drugs Aging. 2009;26(8):677–686.

14.

Dwyer

Gabbe

Stoelwinder

Lowthian

. A systematic review of outcomes following emergency transfer to hospital for residents of aged care. Age Ageing. 2014;43(6):759–766.

15.

Naranjo

Busto

Sellers

, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245.

16.

National Institutes of Health. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda, MD: U.S. National Library of Medicine; 2017. https://livertox.nih.gov/Narajo.html.

17.

Frawley

Finney-Brown

. Writing for publication: case studies. Australian Journal of Herbal Medicine. 2013;25(3):1–3.